Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDActual EPS
CRISPR Therapeutics AG Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2025 | 12 | -$1.48 | -$0.88 | -$1.21 |
| Q2 2025 | 6 | -$1.21 | -$1.21 | -$1.21 |
| Q3 2025 | 6 | -$1.18 | -$1.18 | -$1.18 |
| Q4 2025 | 7 | -$1.11 | -$1.11 | -$1.11 |
| Q1 2026 | 10 | -$1.14 | -$1.14 | -$1.14 |
| Q2 2026 | 9 | -$1.09 | -$1.09 | -$1.09 |
| Q3 2026 | 9 | -$1.03 | -$1.03 | -$1.03 |
| Q4 2026 | 10 | -$0.96 | -$0.96 | -$0.96 |
CRISPR Therapeutics AG Earnings Date And Information
CRISPR Therapeutics AG last posted its earnings results on Tuesday, February 11th, 2025. The company reported $-0.44 earnings per share for the quarter, topping analysts' consensus estimates of $-1.15 by $0.71. The company had revenue of 35.00 M for the quarter and had revenue of 35.00 M for the year. CRISPR Therapeutics AG has generated $-4 earnings per share over the last year ($-4.34 diluted earnings per share) and currently has a price-to-earnings ratio of -7.88. CRISPR Therapeutics AG has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, May 6th, 2025 based on prior year's report dates.
CRISPR Therapeutics AG Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 02/11/2025 | Q4 2024 | -$1.15 | -$0.44 | 0.71 | $8.06 M | $35.00 M |
| 11/05/2024 | Q3 2024 | -$1.33 | -$1.01 | 0.32 | $6.54 M | $602,000 |
| 08/05/2024 | Q2 2024 | -$1.37 | -$1.49 | -0.12 | $12.06 M | $517,000 |
| 05/08/2024 | Q1 2024 | -$1.63 | -$1.43 | 0.2 | $24.34 M | $504,000 |
| 02/21/2024 | Q4 2023 | -$0.07 | $1.12 | 1.19 | $140.94 M | $200.00 M |
| 11/06/2023 | Q3 2023 | -$1.98 | -$1.41 | 0.57 | $11.89 M | $0 |
| 08/07/2023 | Q2 2023 | -$2.18 | -$0.98 | 1.2 | $1.80 M | $70.00 M |
| 05/08/2023 | Q1 2023 | -$1.67 | -$0.67 | 1 | N/A | $100.00 M |
| 02/21/2023 | Q4 2022 | -$2.32 | -$1.41 | 0.91 | N/A | $6,000 |
| 11/01/2022 | Q3 2022 | -$2.30 | -$2.24 | 0.06 | $1.85 M | $94,000 |
| 08/08/2022 | Q2 2022 | -$2.23 | -$2.40 | -0.17 | $2.21 M | $158,000 |
| 05/09/2022 | Q1 2022 | -$1.91 | -$2.32 | -0.41 | N/A | $178,000 |
| 02/15/2022 | Q4 2021 | -$1.74 | -$1.84 | -0.1 | N/A | $12.35 M |
| 11/03/2021 | Q3 2021 | -$1.69 | -$1.67 | 0.02 | $1.23 M | $329,000 |
| 07/29/2021 | Q2 2021 | $3.52 | $10.01 | 6.49 | $900.19 M | $900.20 M |
| 04/27/2021 | Q1 2021 | -$1.45 | -$1.51 | -0.06 | N/A | $202,000 |
| 02/16/2021 | Q4 2020 | -$1.23 | -$1.53 | -0.3 | N/A | $194,000 |
| 10/28/2020 | Q3 2020 | -$1.17 | -$1.32 | -0.15 | $1.92 M | $148,000 |
| 07/27/2020 | Q2 2020 | -$0.92 | -$1.30 | -0.38 | $18.13 M | $44,000 |
| 04/28/2020 | Q1 2020 | -$1.09 | -$1.15 | -0.06 | N/A | $157,000 |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
CRISPR Therapeutics AG Earnings: FAQ's
CRISPR Therapeutics AG has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, May 6th, 2025 based offlast year's report dates.
In the previous quarter, CRISPR Therapeutics AG (:CRSP) reported $-0.44 earnings per share (EPS) to beat the analysts' consensus estimate of $-1.15 by $0.71.
The conference call for CRISPR Therapeutics AG's latest earnings report can be listened to online.
The conference call transcript for CRISPR Therapeutics AG's latest earnings report can be read online.
CRISPR Therapeutics AG (:CRSP) has a recorded annual revenue of $35.00 M.
CRISPR Therapeutics AG (:CRSP) has a recorded net income of $-366,252,000.CRISPR Therapeutics AG has generated $-4.34 earnings per share over the last four quarters.
CRISPR Therapeutics AG (:CRSP) has a price-to-earnings ratio of -7.88 and price/earnings-to-growth ratio is 0.14.